Yellow fever vaccines

Biologicals

Volumn 25, Issue 1, 1997, Pages 17-25

  Barrett, Alan D T ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; MONOCLONAL ANTIBODY; YELLOW FEVER VACCINE;

CHICK EMBRYO; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SCREENING; FLAVIVIRUS; IMMUNITY; INFECTION CONTROL; MOLECULAR CLONING; PRIORITY JOURNAL; REVIEW; VIRUS ATTENUATION; VIRUS VIRULENCE; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

FLAVIVIRUS; YELLOW FEVER VIRUS;

EID: 0031106066     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1997.0056     Document Type: Article

References (67)

1. 1. Barrett ADT. Yellow fever vaccines. Bull Inst Past 1987; 85: 103-124.
2. 2. Mathis C, Sellards AW, Langret J. Sensibilite du Maca Rhesus au virus de la fievre jaune. Comptes Rendus Hebdomadaire des Seances de l'Academie des Sciences 1928; 186: 604-606.
3. 3. Theiler M, Smith HH. Effect of prolonged cultivation in vivo upon pathogenicity of yellow fever virus. J Exp Med 1937; 65: 767-786.
4. 4. Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937; 65: 787-800.
5. 5. Whitman L. Failure of Aedes aegypti to transmit yellow fever cultured virus (17D). Am J Trop Med Hyg 1939; 19: 19-26.
6. 6. Deubel V, Camicas JL, Pandare D et al. Developpement de souches sauvages et vaccinales du virus de la fievre jaune dans les cellules de Aedes aegypti et transmission au souriceau. Annals Virol 1981; 132E: 41-50.
7. 7. Barrett ADT, Mathews JH, Miller BR et al. Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus. J Gen Virol 1990; 71: 13-18.
8. 8. Dick GWA. Vaccination by scarification with 17D chick-embryo vaccine. In Yellow Fever Vaccination, WHO Monograph Series 1956; no. 30: 97-103.
9. 9. Smith HH. Controlling yellow fever. In Strode GK, ed., Yellow Fever. 1951; 539-628.
10. 10. McNamara FN. Reactions following neurotropic yellow fever vaccine given by scarification in Nigeria. Trans Roy Soc Trop Med Hyg 1953; 47: 199-208.
11. 11. World Health Organization. Yellow fever vaccination. WHO Monograph Series 1956; no. 30, Geneva.
12. 12. Theiler M. The virus. In Yellow fever, Strode GK, ed., 1951; pp. 43-146.
13. 13. Fox JP, Lennette EH, Monso C et al. Encephalitis in man following vaccination with 17D yellow fever virus. Am J Hyg 1942; 36: 117-141.
14. 14. World Health Organization. Standards for the manufacture and control of yellow fever vaccine. United Nations Relief and Rehabilitation Administration. WHO Epidemiological Bulletin 1945; 1: 1-365.
15. 15. Waters TD, Anderson PS, Beebe GW et al. Yellow fever vaccination, avian leukosis virus and cancer risk in man. Science 1972; 177: 76-77.
16. 16. Expert Committee on Biological Standarization. WHO Tech Rep Ser 1981; 658.
17. 17. Expert Committee on Biological Standarization. WHO Tech Rep Ser 1987; 745.
18. 18. Expert Committee on Biological Standarization. WHO Tech Rep Ser 1992; 822.
19. 19. Aylward B, Kane M, Batson A et al. A framework for the evaluation of vaccines for use in the expanded programme on immunization. Vaccine 1994; 12: 1155-1159.
20. 20. Liprandi F. Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus. J Gen Virol 1981; 56: 363-370.
21. 21. Barrett ADT, Gould EA. Compariosn of the neurovirulence of different strains of yellow fever virus in mice. J Gen Virol 1986; 67: 631-637.
22. 22. Liprandi F, Walder R. Replication of virulent and attenuated strains of yellow fever virus in human monocytes and macrophage-like cells (U937). Arch Virol 1983; 76: 51-61.
23. 23. Buckley A, Gould EA. Neutralization of yellow fever virus studied using monoclonal and polyclonal antibodies. J Gen Virol 1985; 66: 2523-2531.
24. 24. Barrett ADT, Pryde A, Medlen AR et al. Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodies. Vaccine 1989; 7: 333-336.
25. 25. Ledger TN, Sil BK, Wills MR et al. Variation in the biological functions of envelope protein epitopes of yellow fever vaccine viruses detected with monoclonal antibodies. Biologicals 1992; 20: 117-128.
26. 26. Gould EA, Buckley A, Cammack N et al. Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies. J Gen Virol 1985; 66: 1369-1382.
27. 27. Gould EA, Buckley A, Barrett ADT et al. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confers immunity in mice. J Gen Virol 1986; 67: 591-595.
28. 28. Schlesinger JJ, Brandriss MW, Monath TP. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition and immune precipitation of the virus envelope. Virology 1983; 125: 8-17.
29. 29. Brandriss MW, Schlesinger JJ, Walsh EE et al. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 1986; 67: 229-234.
30. 30. Monath TP, Kinney RM, Schlesinger JJ et al. Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide. J Gen Virol. 1983; 64: 627-637.
31. 31. Gould EA, Buckley A, Cane PA et al. Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. J Gen Virol 1989; 70: 1894-1899.
32. 32. Sil BK, Dunster LM, Ledger TN et al. Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus. J Virol 1992; 66: 4265-4270.
33. 33. Barrett ADT, Monath TP, Cropp CB et al. Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol 1990; 71: 2301-2306.
34. 34. Cammack, N, Gould EA. Topographical analysis of epitope relationships on the envelope glycoprotein of yellow fever 17D vaccine and the wild type Asibi parent strain. Virology 1986; 150: 333-341.
35. 35. Schlesinger JJ, Walsh EE, Brandriss MW. Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. J Gen Virol 1984; 65: 1637-1644.
36. 36. Expert Committee on Biological Standardization. Requirements for yellow fever vaccine. WHO Tech Rep Ser 1976; 594.
37. 37. de Souza Lopes O, de Almeida Guimares SSD, de Carvalho R. Studies on yellow fever vaccine II. Stability of the reconstituted product. J Biol Stand 1988; 16: 71-76.
38. 38. Barme M, Bronnert C. Thermo stabilisation du vaccin anti-amaril 17D lyophilise - 1. Essai de substances protectrices J Biol Stand 1984; 12: 435-442.
39. 39. Georges A-J, Tible F, Meunier D-M-Y et al. Thermo stability and efficacy in the field of a new, stabilized yellow fever virus vaccine. Vaccine 1985; 3: 313-315.
40. 40. Seagroatt V, Magrath DI. A WHO collaborative study of in vitro and in vivo methods for the assay of yellow fever vaccines. J Biol Stand 1983; 11: 47-54.
41. 41. Sood DK, Aggarwal RK, Kumar S et al. A rapid test for measuring the infectivity of yellow fever vaccine. Vaccine 1995; 13: 427-428.
42. 42. De Souza Lopes O, de Almeida Guimares SSD, de Carvalho R. Studies on yellow fever vaccine III. Dose response in volunteers. J Biol Stand 1988; 16: 77-82.
43. 43. Freestone DS, Ferris RD, Weinberg AL et al. Stabilized 17D strain yellow fever vaccine: dose response studies, clinical reactions and effects on hepatic function. J Biol Stand 1977; 5: 181-186.
44. 44. de Souza Lopes O, de Almeida Guimaras SSD, de Carvalho R. Studies on yellow fever vaccine I. Quality-control parameters. J Biol Stand 1987; 15: 323-329.
45. 45. Levenbook IS, Pelleu LJ, Elisberg BL. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J Biol Stand 1987; 15: 305-313.
46. 46. Tsai TF, Paul R, Lynberg MC et al. Congenital yellow fever virus infection after immunization in pregnancy. J Inf Dis 1993; 168: 1520-1523.
47. 47. Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans Roy Soc Trop Med Hyg 1993; 87: 337-339.
48. 48. Mosimann B, Stoll B, Francillon C, Pecoud A. Yellow fever vaccine and egg allergy. J Allergy Clin Immunol 1995; 95: 1064.
49. 49. Bonnevie-Nielson V, Heron I, Kristensen T et al. Postimmunization activity of oligoadenylate synthetae in peripheral blood lymphocytes from healthy individuals. J Clin Lab Immunol 1989; 28: 155-160.
50. 50. Poland JD, Calisher CH, Monath TP et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull WHO 1981; 59: 895-900.
51. 51. Monath TP, Craven RB, Muth DJ et al. Limitations of the complement fixation test for distinguishing natuarlly acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas. Am J Trop Med Hyg 1980; 29: 624-634.
52. 52. Rice CM, Lenches EM, Eddy SR et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985; 229: 726-733.
53. 53. Hahn CS, Dalymple JM, Strauss JH et al. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine derived from it. Proc Natl Acad Sci USA 1987; 84: 2019-2023.
54. 54. Dupuy A, Despres P, Cahour A et al. Nucleotide sequence compariosn of the genome of two 17D-204 yellow fever vaccines. Nuc Acid Res 1989 17: 3989.
55. 55. Duarte dos Santos CN, Post PR, Carvalho R et al. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 1995; 35: 35-41.
56. 56. Wang E, Ryman KD, Jennings AD et al. Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol 1995; 76: 2749-2755.
57. 57. Post PR, Santos CND, Carvalho R et al. Heterogeneity in envelope protein sequences and N-linked glycosylation among yellow fever vaccine strains. Virology 1992; 188: 160-167.
58. 58. Cane PA, Gould EA. Immunoblotting reveals differences in the accumulation of envelope protein by wild-type and vaccine strains of yellow fever virus. J Gen Virol 1989; 70: 557-564.
59. 59. Rice CM, Grakoui A, Galler R et al. Transcription of infectious yellow fever RNA from full-length templates produced by in vitro ligation. New Biol 1989; 1: 285-296.
60. 60. Marchevsky RS, Mariano J, Ferreira VS et al. Phenotypic analysis of yellow fever virus derived from complementary DNA. Am J Trop Med Hyg 1995; 52: 75-80.
61. 61. Anonymous. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. J Am Med Assoc 1966; 198: 671-672.
62. 62. Jennings AD, Gibson CA, Miller BR et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Inf Dis 1994; 169: 512-518.
63. 63. Schoub BD, Dommann CJ, Johnson S et al. Encephalitis in a 13-year-old boy following 17D yellow fever vaccine. J Infect 1990; 21: 105-106.
64. 64. Drouet A, Chagnon A, Valance J et al. Meningo-encephalite apres vaccination anti-amarile par la souche 17D: deux observations. Revue de Medecine Interne 1993; 14: 257-259.
65. 65. Merlo C, Steffen R, Landis T et al. Possible association of encephalitis and 17D yellow fever vaccination in a 29-year-old traveller. Vaccine 1993; 11: 691.
66. 66. Lepineic L, Dalgarno L, Huong VTQ et al. Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. J Gen Virol 1994; 75: 417-423.
67. 67. Jennings AD, Whitby JE, Minor PD et al. Comparison of the nucleotide and deduced amino acid sequence of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses. Vaccine 1993; 11: 679-681.